Literature DB >> 20409221

Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report.

Tatsuya Kinoshita1, Hitoshi Inoue, Toshiro Kinouchi, Masao Kobayashi, Tsuyoshi Takada, Tsuneo Hara, Koji Hatano, Norio Nonomura.   

Abstract

We present the case of a patient with renal cell carcinoma treated preoperatively with sorafenib. Complete resection of the left renal mass measuring 7.2 x 6.6 cm seemed to be difficult at diagnosis because of large renal hilar lymph nodes. With a short period of sorafenib administration, marked shrinkage of the renal mass and lymphadenopathy was observed after the patient experienced fulminant hepatic failure and a severe hand-foot skin reaction. Two-dimensional computed tomography revealed 60%, 78% and 84% reduction in the primary renal tumor, lung metastatic nodules and lymph nodes, respectively. Tumor shrinkage allowed for complete resection of the left kidney and the lymphadenopathy. Pathological findings revealed that over 90% of the renal tumor was substituted by necrotic fibrotic tissue and that the residual neoplastic component was diagnosed as clear cell carcinoma. The lymph nodes that were resected were negative for malignancy. At 6 months after radical nephrectomy, a new computed tomography scan revealed no evidence of disease with the disappearance of lung nodules.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20409221     DOI: 10.1111/j.1442-2042.2009.02444.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  2 in total

Review 1.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Authors:  John M L Ebos; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

2.  Complete response to low-dose sorafenib in a patient with metastatic renal cell carcinoma: A case report.

Authors:  Jun Morita; Michio Naoe; Yu Ogawa; Takehiko Nakasato; Motoko Sugahara; Masashi Morita; Kohzo Fuji; Takashi Fukagai; Haruaki Sasaki; Yoshio Ogawa
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.